RE: Iliad fund raise1 Dec 2025 08:44
stop talking ****e..nothing has been raised recently..
ai overview
iliad biotechnologies has raised over $100 million to fund its operations and the development of its lead product, the bpze1 pertussis vaccine. its most recent public funding was a series d round of $42.8 million in september 2022, led by knott partners, to support a phase 2b human challenge study for the vaccine. the company has also secured an additional €10 million from the european union for early research.
total funding: over $100 million raised to date.
latest funding round: $42.8 million in series d financing in september 2022.
purpose of latest funding: to fund continued operations, r&d, manufacturing development for the bpze1 vaccine, and further clinical studies, including a phase 2b human challenge study.
additional funding: €10 million from the european union for early research.
key investors: knott partners (lead investor in the series d round), national institutes of health, thylacine capital, endo investors, and network-1 technologies.
most recent funding round: a series d round on december 15, 2023, with an undisclosed amount, led by livent.